Evaluate Time Associated with the Preparation & Administration of Denosumab/Pamidronate in Patients with Solid Tumors and Metastatic Bone Disease

- Diagnosis of metastatic bone disease secondary to a solid tumor (eg, breast cancer, lung cancer, etc). - An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Subject is one of the following: o being considered for pamidronate IV infusions or denosumab SC injections for treatment of metastatic bone disease (prescribed per Canadian product monograph); OR o scheduled to receive pamidronate IV infusions or denosumab SC injections for treatment of metastatic bone disease (prescribed per Canadian product monograph); OR o currently receiving pamidronate IV infusions or denosumab SC injections for treatment of metastatic bone disease AND has received no more than 4 prior administration of either product combined (prescribed per Canadian product monograph). - Subject has a serum calcium or albumin-adjusted serum calcium ≥ 2.0 mmol/L (8.0 mg/dL) and ≤ 2.9 mmol/L (11.5 mg/dL)

- Diagnosis with metastatic bone disease secondary to multiple myeloma or prostate cancer. - Severe renal impairment (creatinine clearance < 30 mL/min) - Subject is being considered for ambulatory pamidronate administration using an infuser device (ie, “baby bottle”). - A known active infection with Hepatitis B virus or Hepatitis C virus. - Subject has known positive results for human immunodeficiency virus (HIV).Subject has a history of other malignancy within the past 5 years, other than: • Malignancy treated with curative intent and with no known active disease present for ≥ 5 years before enrollment and felt to be at low risk for recurrence by the treating physician • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease • Adequately treated cervical carcinoma in situ without evidence of disease • Adequately treated breast ductal carcinoma in situ without evidence of disease • Prostatic intraepithelial neoplasia without evidence of prostate cancer • Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ. - Subject has a history or current evidence of osteonecrosis/osteomyelitis of the jaw, active dental or jaw condition that requires oral surgery, non-healed dental/oral surgery, or planned invasive dental procedure over the course of the study.